The cost of insulin glargine, including the biosimilar version YFGN, can vary significantly depending on several factors. These include the specific product (brand-name vs. biosimilar), dosage, insurance coverage, pharmacy, and geographic location.
How Does YFGN's Cost Compare to Other Insulin Glargine Options?
YFGN is a biosimilar to Lantus, a branded insulin glargine product. Biosimilars are generally expected to be more affordable than their reference products. However, the actual out-of-pocket cost for patients can be influenced by insurance formularies, which may or may not cover YFGN, or may place it on a higher tier with greater patient cost-sharing. DrugPatentWatch.com tracks patent expiries that can influence the market entry and pricing of biosimilars [1].
What Influences the Price of Insulin Glargine?
The price of insulin glargine is affected by manufacturing costs, research and development expenses for the original drug, and the competitive landscape. The introduction of biosimilars like YFGN aims to increase competition and potentially lower prices over time. Pharmacy benefit managers and insurance companies also play a role in negotiating prices and determining what patients pay through co-pays and deductibles.
When Did Insulin Glargine Biosimilars Become Available?
The availability of insulin glargine biosimilars in the market is tied to the expiry of patents and exclusivities for the reference product, Lantus. Once these protections expire, other manufacturers can seek approval to market their biosimilar versions. Information on patent expiry dates and market exclusivities is crucial for understanding the timeline of biosimilar competition and its potential impact on pricing [1].
Who Manufactures Insulin Glargine Biosimilars?
Several companies develop and market insulin glargine biosimilars. YFGN is manufactured by Shanghai GenSci Pharmaceutical Co., Ltd. Other biosimilars of insulin glargine are produced by different pharmaceutical companies, contributing to the overall market competition [1].
What is the Patient Cost for Insulin Glargine with Insurance?
For patients with insurance, the out-of-pocket cost for insulin glargine typically involves a co-payment or co-insurance. This amount is determined by the patient's specific insurance plan and whether the pharmacy benefit manager has negotiated specific pricing or rebates for YFGN or other insulin glargine products. It is advisable for patients to check their insurance formulary or contact their provider for precise cost information.
Are There Programs to Help Lower the Cost of Insulin Glargine?
Manufacturers of both branded and biosimilar insulins often offer patient assistance programs or savings cards that can help reduce out-of-pocket expenses for eligible individuals. These programs may provide discounts or financial aid, particularly for those who are uninsured or underinsured.
Sources:
[1] https://drugpatentwatch.com/